Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)

Jittamala P. et al, (2024)

Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)

Wongnak P. et al, (2024)

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial.

Luvira V. et al, (2024), BMC Infect Dis, 24

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.

Schilling WHK. et al, (2024), Lancet Infect Dis, 24, 36 - 45

Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV).

Jittamala P. et al, (2023), J Infect Dis, 228, 1318 - 1325

Reflections on Participation in a Trial on Hydroxychloroquine as Prevention for COVID-19 among Health Workers in Niger.

Kabore Y. et al, (2023), Am J Trop Med Hyg, 109, 511 - 514

Raising awareness of antimicrobial resistance: development of an 'antibiotic footprint calculator'.

Prapharsavat R. et al, (2023), J Antimicrob Chemother, 78, 1317 - 1321

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open- label, randomised, controlled adaptive platform trial

Luvira V. et al, (2023)

Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV).

Schilling WHK. et al, (2023), Elife, 12

Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants

Jittamala P. et al, (2022)

Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19

Schilling WHK. et al, (2022)

Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project

Chandna A. et al, (2022), Wellcome Open Research, 6, 64 - 64

Improving empiric antibiotic prescribing in pediatric bloodstream infections: a potential application of weighted-incidence syndromic combination antibiograms (WISCA).

Cook A. et al, (2022), Expert Rev Anti Infect Ther, 20, 445 - 456

Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study

Perrone C. et al, (2022), Wellcome Open Research, 6

Does hydroxychloroquine still have any role in the COVID-19 pandemic?

Schilling WH. and White NJ., (2021), Expert Opin Pharmacother, 22, 1257 - 1266

Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study.

Perrone C. et al, (2021), Wellcome open research, 6

Automating the Generation of Antimicrobial Resistance Surveillance Reports: Proof-of-Concept Study Involving Seven Hospitals in Seven Countries (Preprint)

Lim C. et al, (2020)

Include forthcoming?